Effects of Pain Scrambler Therapy for the Alterations of Cerebral Blood
Launched by HANGANG SACRED HEART HOSPITAL · Mar 5, 2019
Trial Information
Current as of April 24, 2025
Unknown status
Keywords
ClinConnect Summary
The groups (scrambler therapy and sham therapy) were randomly assigned. All subjects were recruited in scrambler thrapy and sham stimulation. Main study outcomes included group differences in CBV changed and the the relationship between CBV changes and neuropathic pain intensity. These analyses were performed using the same framework of the general linear model, which was repeatedly applied to each voxel with the same coordinates.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Burn patients
- • severe neuropatic pain rated at least 5 on the 10-point numerical rating scale (NRS)
- Exclusion Criteria:
- • cardiac arrest history
- • history of neurologi disease or brain surgery
- • unstable heart disease or presence of a cardiac pacemaker
- • pain resulting from other causes like as neuromuscular diseases
- • psychiatric disorder
- • diabetes mellitus
- • abnormal renal function
- • contraindication for MRI, or pregnancy.
Trial Officials
Cheong Hoon Seo, M.D.
Principal Investigator
Hangang Sacred Heart Hospital
About Hangang Sacred Heart Hospital
Hangang Sacred Heart Hospital is a prominent healthcare institution dedicated to advancing medical research and patient care. With a strong commitment to innovation and excellence, the hospital serves as a key clinical trial sponsor, facilitating cutting-edge studies that aim to enhance treatment options and improve health outcomes. Equipped with state-of-the-art facilities and a team of experienced researchers and healthcare professionals, Hangang Sacred Heart Hospital prioritizes ethical standards and patient safety in all its clinical trials, fostering collaboration with academic institutions and industry partners to drive meaningful advancements in medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, Yeong Deungpo Dong, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials